Fig. 3
The activation and function of SIRPα Shp2-iSNAP on phagocytosis of cancer cells. a and b Images of a representative BMDM expressing SIRPα Shp2-iSNAP before and after incubation with 10 μg ml−1 rituximab-opsonized Toledo cells a or 2 μg ml−1 cetuximab-opsonized DLD1 b at indicated time points. c The FRET ratio of SIRPα Shp2-iSNAP in the BMDM at the region around the engaging Toledo cell before, during and after phagocytosis (n = 7, 7, 7). The same colored dots represent data obtained from the same cell. d, e Dot plot of normalized phagocytic rate (mean ± s.e.m.) of macrophages expressing different constructs as described in Fig. 2 against rituximab-opsonized Toledo d (n = 6, 5, 6, 6, 5) or cetuximab-opsonized DLD1 cells e (n = 8, 8, 8, 8, 8). *P < 0.05, **P < 0.01, ***P < 0.001 (two-sided Mann–Whitney U-test adjusted for multiple group comparison). Scale bars, 20 μm
